A detailed history of Geneos Wealth Management Inc. transactions in Lucid Diagnostics Inc. stock. As of the latest transaction made, Geneos Wealth Management Inc. holds 33,850 shares of LUCD stock, worth $25,726. This represents 0.0% of its overall portfolio holdings.

Number of Shares
33,850
Previous 33,850 -0.0%
Holding current value
$25,726
Previous $27,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Jan 30, 2023

SELL
$1.21 - $2.27 $8,470 - $15,890
-7,000 Reduced 17.14%
33,850 $46,000
Q3 2022

Nov 14, 2022

SELL
$1.53 - $3.45 $2,448 - $5,520
-1,600 Reduced 3.77%
40,850 $62,000
Q2 2022

Jul 22, 2022

SELL
$1.73 - $3.44 $34,600 - $68,800
-20,000 Reduced 32.03%
42,450 $95,000
Q1 2022

May 16, 2022

BUY
$2.85 - $5.24 $177,982 - $327,238
62,450 New
62,450 $209,000

Others Institutions Holding LUCD

About Lucid Diagnostics Inc.


  • Ticker LUCD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 38,568,500
  • Market Cap $29.3M
  • Description
  • Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarc...
More about LUCD
Track This Portfolio

Track Geneos Wealth Management Inc. Portfolio

Follow Geneos Wealth Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geneos Wealth Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Geneos Wealth Management Inc. with notifications on news.